Drugs / Claseprubart
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT06537999 | Sep 2024 → Jun 2026 overdue | multifocal motor neuropathy | Dianthus Therapeutics | Recruiting | No outcome recorded |
| Phase 2 | NCT06282159 | Feb 2024 → Jul 2025 overdue | generalized myasthenia gravis | Dianthus Therapeutics | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07647510 | Jul 2026 → Dec 2028 expected | generalized myasthenia gravis | Dianthus Therapeutics | Recruiting | No outcome recorded |
| Phase 3 | NCT06858579 | Feb 2025 → Dec 2028 expected | polyneuropathy, inflammatory demyelinating, chronic | Dianthus Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-03-09 | Dianthus Therapeutics | Results Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results dianthustx.com ↗
Early GO decision reached in CAPTIVATE ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Phase 3 registrational trial of claseprubart |
| 2026-03-09 | Dianthus Therapeutics | Results Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) dianthustx.com ↗
Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced an early GO decision based on an interim responder analysis in the Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). |
| 2025-10-29 | Dianthus Therapeutics | Results Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting dianthustx.com ↗
During AANEM, Dr. Pushpa Narayanaswami, MD from Harvard Medical School presented the successful Phase 2 MaGic trial data for the first time at a medical conference. |
| 2025-09-08 | Dianthus Therapeutics | Results Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile dianthustx.com ↗ |
All press releases naming this drug 9 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Claseprubart | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07647510 ↗ |
| Route | Intravenous | “Day 1: IV loading dose” NCT06282159 ↗ |